Alogliptin: a new addition to the class of DPP-4 inhibitors

Figures & data

Table 1 Summary of the clinical efficacy of alogliptin as mono and combination therapy

Study	N	Wks	Baseline HbA1c (%)	Intervention	Change from baseline			Hypoglycemia (%)a	Severe hypoglycemia (%)b
					HbA1c (%)	FPG (mg/dL)	Weight (kg)
DeFronzo et al 2008^Citation65	329	26	7.9	placebo	0	+11	+0.2	1.6	0
				alogliptin 12.5 mg	−0.6	−10.3	−0.1	3	0
				alogliptin 25 mg	−0.6	−16.4	−0.2	1.5	0
Nauck et al 2009^Citation67	527	26	7.9	placebo + metformin	−0.1	0	−0.4	2.9	0
				alogliptin 12.5 mg + metformin	−0.6	−19	−0.4	0.9	0
				alogliptin 25 mg + metformin	−0.6	−17	−0.7	0	0
Pratley et al 2008^Citation66	500	26	8.1	placebo + glyburide	0	+2.2	−0.2	11.1	0
				alogliptin 12.5 mg + glyburide	−0.4	−4.7	+0.6	15.8	0
				alogliptin 25 mg + glyburide	−0.5	−8.4	+0.7	9.6	0
Pratley et al 2008^Citation68	493	26	8.0	placebo + pioglitazone ± metformin/sulfonylurea	−0.2	−5.7	+1.0	5.2	0
				alogliptin 12.5 mg + pioglitazone ± metformin/sulfonylurea	−0.7	−19.7	+1.5	5.1	0
				alogliptin 25 mg + pioglitazone ± metformin/sulfonylurea	−0.8	−19.9	+1.1	7.0	0
Rosenstock et al 2008^Citation69	390	26	9.3	placebo + insulin ± metformin	−0.1	5.8	0.6	24	0.5
				alogliptin 12.5 mg + insulin ± metformin	−0.6	2.3	0.7	26.7	0
				alogliptin 25 mg + insulin ± metformin	−0.7	−11.7	0.6	27.1	0.25

a Hypoglycemia defined as blood glucose <70 mg/dL.

b Severe hypoglycemia defined as symptomatic hypoglycemia requiring another person’s assistance.

Abbreviation: FPG, fasting plasma glucose.

DefronzoRFleckPWilsonCMekkiQAlogliptin Study 010 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care2008312315231718809631

 PubMed Web of Science ®Google Scholar

NauckMEllisGFleckPWilsonCMekkiQAlogliptin Study 008 GroupEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled studyInt J Clin Pract2009631465519125992

 PubMed Web of Science ®Google Scholar

PratleyRKipnesMFleckPWilsonCMekkiQAlogliptin Study 007 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapyDiabetes Obes Metab200911216717619125778

 PubMed Web of Science ®Google Scholar

PratleyRReuschJFleckPWilsonCMekkiQAlogliptin added to pioglitazone therapy improves glycemic control in patients with type 2 diabetes without increasing weight gain or hypoglycemia [abstract]Diabetologia200851Suppl 1S343

 Google Scholar

RendellMRosenstockJGrossJFleckPWilsonCMekkiQAddition of Alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycemia in patients with type 2 diabetes [abstract]Diabetologia200851Suppl 1S37

 Google Scholar